Loading…
Innoviva, Inc. is projected to rise to $23.50 by 2027, a +12% move from its current price of $20.97. INVA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $20.71 | $20.98 | $21.26 | +0.06% |
| Aug 3 | $20.61 | $21.00 | $21.39 | +0.12% |
| Aug 4 | $20.54 | $21.01 | $21.49 | +0.19% |
| Aug 5 | $20.48 | $21.02 | $21.58 | +0.25% |
| Aug 6 | $20.43 | $21.03 | $21.66 | +0.31% |
| Aug 7 | $20.38 | $21.05 | $21.73 | +0.37% |
| Aug 8 | $20.34 | $21.06 | $21.80 | +0.43% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $20.34 | $21.06 | $21.80 | +0.43% |
| Week 2 | $20.14 | $21.15 | $22.21 | +0.87% |
| Week 3 | $20.01 | $21.24 | $22.55 | +1.30% |
| Week 4 | $19.91 | $21.34 | $22.86 | +1.74% |
| Week 5 | $19.83 | $21.43 | $23.15 | +2.18% |
| Week 6 | $19.77 | $21.52 | $23.42 | +2.63% |
| Week 7 | $19.72 | $21.61 | $23.68 | +3.07% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI.
The company markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of Staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases.
It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc.
in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Innoviva, Inc. (INVA) is a healthcare company with a $1.58B market capitalization and a current price of $21.43. It ranks 2130 by market cap among listed equities. The stock sits in a continuing price context with a price outlook shaped by a multi-year forecast that envisions substantial upside over time.
Near term, the technical snapshot shows a bullish tilt with a 30-day technical backdrop that complements the longer horizon forecast. The asset’s near-term path is supported by a structured level set of price markers and volatility embedded in the forecast horizon.
A major floor 8.5% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 12.7% above — a clean break opens room to run.
A major ceiling 17.0% above — clearing it would confirm fresh momentum.
Key INVA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of INVA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $21.39 | Sell | $21.29 | Sell |
| MA 10 | $21.39 | Sell | $21.45 | Sell |
| MA 20 | $21.73 | Sell | $21.71 | Sell |
| MA 50 | $22.18 | Sell | $22.09 | Sell |
| MA 100 | $22.55 | Sell | $22.12 | Sell |
| MA 200 | $21.52 | Sell | $21.58 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.88 | Neutral |
| Stoch RSI (14) | 6.19 | Buy |
| CCI (20) | -143.86 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -4.20 | Sell |
| Bollinger %B (20,2) | 0.04 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.18 | Sell |
| Awesome (5,34) | -0.80 | Sell |
| Ultimate (7,14,28) | 37.84 | Neutral |
| Momentum (10) | -0.74 | Sell |
| Aroon Osc (25) | -96.00 | Sell |
| Hull MA (9) | 21.36 | Sell |
| ADX (14) | 13.77 | Neutral |
| ATR (14) | 0.30 | Info |
Technical snapshot (30-day window): sentiment is BULLISH with RSI(14) at 40. The 50-day simple moving average (SMA50) is $22.32 and the 200-day simple moving average (SMA200) is $21.38. Support is at $21.28 and resistance at $23.64. The 30-day price range runs from $19.59 to $23.45. Annualized volatility is 30%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $19.31 | $20.97 | $27.63 | 0% | Neutral | |
| $19.27 | $23.50 | $29.95 | +12% | Neutral | |
| $22.24 | $27.63 | $36.18 | +32% | Bullish | |
| $27.18 | $34.31 | $45.89 | +64% | Bullish | |
| $28.88 | $36.95 | $50.32 | +76% | Bullish | |
| $30.83 | $39.93 | $55.24 | +90% | Bullish | |
| $32.68 | $42.79 | $60.05 | +104% | Bullish | |
| $33.87 | $44.83 | $63.73 | +114% | Bullish | |
| $35.65 | $47.65 | $68.55 | +127% | Bullish | |
| $39.75 | $53.65 | $78.04 | +156% | Bullish | |
| $53.50 | $75.31 | $114.82 | +259% | Bullish | |
| $113.33 | $171.09 | $279.65 | +716% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $19.31 | $20.97 | $25.76 | +0.00% |
| September 2026 | $19.07 | $22.37 | $26.82 | +6.65% |
| October 2026 | $18.83 | $22.18 | $26.80 | -0.81% |
| November 2026 | $18.68 | $22.09 | $26.85 | -0.43% |
| December 2026 | $19.06 | $22.61 | $27.63 | +2.36% |
Click any year to see its month-by-month INVA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, INVA could reach as high as $27.63, with a base case around $20.97 and support toward $19.31 — roughly 0% from $20.97. A consolidation phase looks the most probable path here.
Expect INVA to range from $19.27 to $29.95 through 2027. The $23.50 average target implies a +12% move from current prices. That is up +12% on the projected 2026 average. Price action looks broadly range-bound.
The INVA price prediction for 2028 points to an average of $27.63 (low $22.24, high $36.18) — a potential gain of +32% on today's $20.97. Buyers look set to stay in control over this stretch.
In 2029, INVA is projected to trade between $27.18 and $45.89, averaging $34.31 — a potential gain of +64% from today's $20.97. That is up +24% on the projected 2028 average. Momentum favours further upside here.
Innoviva, Inc.'s 2030 outlook centres on $36.95, within a $28.88 to $50.32 range. That is up +8% on the projected 2029 average. That marks a +76% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, INVA could reach as high as $55.24, with a base case around $39.93 and support toward $30.83 — roughly +90% from $20.97. Momentum favours further upside here.
Expect INVA to range from $32.68 to $60.05 through 2032. The $42.79 average target implies a +104% move from current prices. That is up +7% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The INVA price prediction for 2033 points to an average of $44.83 (low $33.87, high $63.73) — a potential gain of +114% on today's $20.97. Momentum favours further upside here.
In 2034, INVA is projected to trade between $35.65 and $68.55, averaging $47.65 — a potential gain of +127% from today's $20.97. That is up +6% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Innoviva, Inc.'s 2035 outlook centres on $53.65, within a $39.75 to $78.04 range. That is up +13% on the projected 2034 average. That marks a +156% change versus current levels. Momentum favours further upside here.
By 2040, INVA could reach as high as $114.82, with a base case around $75.31 and support toward $53.50 — roughly +259% from $20.97. Buyers look set to stay in control over this stretch.
Expect INVA to range from $113.33 to $279.65 through 2050. The $171.09 average target implies a +716% move from current prices. That is up +127% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in INVA today (≈ 47.687172 INVA) could be worth
$8,158.79
+$7,158.79 (+716%) by 2050 · US Dollar
Based on the average projected INVA price of $171.09 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in INVAwould be worth at today's price.
$1,000 invested in INVA on Jul 31, 2025 (≈ 55.035773 INVA) would be worth
$1,154.1
+$154.1 (+15.4%) today · 1.15× · US Dollar
Based on a INVA entry price of $18.17 vs. today's $20.97.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $21.44 | $978.08 | -2.2% |
| 1 month ago | $21.9 | $957.53 | -4.2% |
| 3 months ago | $23.11 | $907.4 | -9.3% |
| 6 months ago | $20.98 | $999.52 | -0.0% |
| 1 year ago | $18.17 | $1,154.1 | +15.4% |
| All time (5.0y) ago | $14.61 | $1,435.32 | +43.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our INVA forecast.
Our base-case forecast reaches $42.00 around 2032.
Implied market cap at $42.00: $3.1B
Forecast horizon highlights a strong long-run uptrend. In 2026 the min is $19.31, the avg is $21.43, and the max is $28.52, with ROI 0 and sentiment NEUTRAL. In 2027 the min is $19.87, the avg is $24.24, and the max is $30.92, with ROI 13.1 and sentiment NEUTRAL.
In 2028 the min is $23.42, the avg is $29.11, and the max is $38.14, with ROI 35.9 and sentiment BULLISH. In 2029 the min is $28.78, the avg is $36.34, and the max is $48.63, with ROI 69.6 and sentiment BULLISH. In 2030 the min is $30.20, the avg is $38.64, and the max is $52.64, with ROI 80.3 and sentiment BULLISH.
In 2031 the min is $32.77, the avg is $42.45, and the max is $58.75, with ROI 98.1 and sentiment BULLISH. In 2032 the min is $35.02, the avg is $45.88, and the max is $64.41, with ROI 114.1 and sentiment BULLISH. In 2033 the min is $35.80, the avg is $47.40, and the max is $67.40, with ROI 121.2 and sentiment BULLISH.
In 2034 the min is $38.41, the avg is $51.36, and the max is $73.90, with ROI 139.7 and sentiment BULLISH. In 2035 the min is $43.35, the avg is $58.50, and the max is $85.13, with ROI 173 and sentiment BULLISH. By 2040 the min is $58.77, the avg is $82.73, and the max is $126.16, with ROI 286.1 and sentiment BULLISH.
By 2050 the min is $124.84, the avg is $188.51, and the max is $308.17, with ROI 779.6 and sentiment BULLISH.
Tap a question to reveal the answer.
2030 forecast shows min $30.20, avg $38.64, max $52.64; ROI 80.3; sentiment BULLISH.
2040 forecast shows min $58.77, avg $82.73, max $126.16; ROI 286.1; sentiment BULLISH.
Current price $21.43; Market cap $1.58B; Rank 2130.
2050 forecast shows min $124.84, avg $188.51, max $308.17; ROI 779.6; sentiment BULLISH.
2027 forecast shows min $19.87, avg $24.24, max $30.92; ROI 13.1; sentiment NEUTRAL.
Innoviva, Inc. Community Discussion
0Share your Innoviva, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.